{
  "docId": "019de073-7087-77cd-a846-97dda09bac98",
  "docSlug": "031593eaf739f40f0f0c49214c912ed3",
  "documentTitle": "9 Meters Biopharma | Investor Presentation Deck | 30 slides",
  "authorId": "9-meters-biopharma",
  "authorName": "9 Meters Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 30,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a biological process diagram to illustrate the therapeutic mechanism.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7087-77cd-a846-97dda09bac98/13",
  "deckHref": "/decks/019de073-7087-77cd-a846-97dda09bac98",
  "deckJsonHref": "/decks/019de073-7087-77cd-a846-97dda09bac98.json",
  "deckAnchorHref": "/decks/019de073-7087-77cd-a846-97dda09bac98#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.35,
        "x": 0.6,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Exenatide + XTEN plasmid = Vurolenatide",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "756de092-a748-42b7-907b-466b5e83322e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.08,
        "y": 0.25
      },
      "kind": "image",
      "text": "Diagram showing GLP-1 in blood vs Vurolenatide effect on GI tract",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dcc97bb9-b5e6-4827-8c74-4f72b4c33dbc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.65,
        "y": 0.25
      },
      "kind": "metric",
      "text": "~4.2 kDa",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6cb8ffd0-b9ca-4ab7-8974-8ba45f55acd4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.75,
        "y": 0.8
      },
      "kind": "metric",
      "text": "~80 kDa",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8238ae13-ad72-43e7-8c4e-62cb595d49fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.1,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Short Bowel Syndrome with GLP-1: GLP-1 travels through the blood, which affects gut motility elsewhere in the body.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "28787241-9d1c-49e2-b04c-35008577e90e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.15,
        "y": 0.7
      },
      "kind": "paragraph",
      "text": "Vurolenatide replaces physiological effects of missing GLP-1 to normalize GI transit with twice monthly dosing",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ecc62cc6-7a2a-4abf-8ade-210dc459356d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.4,
        "y": 0.8
      },
      "kind": "paragraph",
      "text": "Motility is slowed, allowing more time for nutrient uptake.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f5da9385-663c-4bb2-89a5-daeb199adc3d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.08,
        "y": 0.1
      },
      "kind": "title",
      "text": "Vurolenatide replaces GLP-1 and restores “ileal brake”",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41851b86-1a04-4aee-8d41-745a307fb86b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "68260452-9520-488e-b9fa-8b188f90f2fc",
      "evidence": "GLP-1 travels through the blood, which affects gut motility elsewhere in the body. Vurolenatide replaces physiological effects of missing GLP-1 to normalize GI transit with twice monthly dosing",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 13,
      "from": 9,
      "beatId": "b99f3106-f3d7-4274-b80d-d8fe2b5cda5a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 9-13 describe the solution Vurolenatide",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}